Ownership and insider activity for Kodiak Sciences Inc. (KOD): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer.
Price
| Price | $97.62 (closing price, November 2, 2026) |
| Market Cap | $6.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-23 | Yang Taiyin | M-Exempt | 20,000 | $47K |
| 2026-10-23 | Yang Taiyin | M-Exempt | 20,000 | $47K |
| 2026-10-21 | BORGESON JOHN A. | M-Exempt | 30,000 | $75K |
| 2026-10-21 | BORGESON JOHN A. | M-Exempt | 30,000 | $75K |
| 2026-10-21 | BORGESON JOHN A. | S-Sale | 8,514 | $746K |
| 2026-10-21 | BORGESON JOHN A. | S-Sale | 1,677 | $150K |
| 2026-10-21 | BORGESON JOHN A. | S-Sale | 7,623 | $684K |
| 2026-10-21 | BORGESON JOHN A. | S-Sale | 5,101 | $464K |
| 2026-10-21 | BORGESON JOHN A. | S-Sale | 2,985 | $274K |
| 2026-10-21 | BORGESON JOHN A. | S-Sale | 2,000 | $185K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.6M | $1.4M | $88.3M | $211.8M | $944.4M | $731.5M | $190.4M | $285.5M | $168.1M | $209.9M |
| Short-term Investments | 0 | 0 | 0 | $124.7M | $24.6M | 0 | $288.5M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.2M | $1.6M | $90.4M | $339.2M | $972.0M | $734.8M | $486.0M | $289.3M | $171.9M | $214.8M |
| Property, Plant & Equipment | $1.8M | $1.5M | $1.1M | $2.8M | $78.8M | $108.1M | $115.8M | $175.0M | $148.7M | $121.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $12.1M | $3.2M | $92.2M | $358.9M | $1.07B | $904.2M | $666.6M | $479.4M | $335.6M | $351.5M |
| Accounts Payable | $1.1M | $3.4M | $1.1M | $2.6M | $8.6M | $12.4M | $9.1M | $13.6M | $3.9M | $12.9M |
| Short-term Debt | 0 | 0 | 0 | $434,000 | 0 | $3.9M | $9.9M | $9.8M | 0 | $12.1M |
| Total Current Liabilities | $2.5M | $9.2M | $4.8M | $11.7M | $31.4M | $64.7M | $52.5M | $41.7M | $25.6M | $45.5M |
| Long-term Debt | 0 | $10.0M | 0 | 0 | 0 | $99.9M | $100.0M | $100.0M | 0 | $100.0M |
| Total Liabilities | $53.2M | $72.0M | $5.4M | $13.5M | $206.6M | $240.9M | $230.5M | $213.6M | $185.3M | $194.2M |
| Retained Earnings | -$41.4M | -$69.3M | -$110.8M | -$158.1M | -$291.2M | -$558.2M | -$892.0M | -$1.15B | -$1.33B | -$1.56B |
| Total Equity | -$41.1M | -$68.7M | $86.8M | $345.4M | $860.8M | $663.3M | $436.2M | $265.8M | $150.3M | $157.4M |
| Total Debt | $185,000 | $10.1M | 0 | $1.9M | $77.4M | $179.9M | $187.7M | $181.6M | $70.3M | $159.2M |
| Net Debt | -$9.4M | $8.7M | -$88.3M | -$334.5M | -$891.6M | -$551.6M | -$291.2M | -$103.9M | -$97.7M | -$50.7M |
| Working Capital | $7.7M | -$7.6M | $85.6M | $327.5M | $940.6M | $670.1M | $433.5M | $247.6M | $146.4M | $169.3M |
Financial Health
| Debt / Equity | 1.57 |
| Current Ratio | 2.49 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.23 |
Profitability
| Return on Equity | -273.23% |
| Return on Invested Capital | -115.23% |
| Return on Assets | -94.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: REGN · BLTE · BLCO · VRTX · 0QZU.L · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of KOD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks